107 related articles for article (PubMed ID: 20364367)
1. Ovarian cancer: predictors of early-stage diagnosis.
Morris CR; Sands MT; Smith LH
Cancer Causes Control; 2010 Aug; 21(8):1203-11. PubMed ID: 20364367
[TBL] [Abstract][Full Text] [Related]
2. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).
Chen AY; Halpern MT; Schrag NM; Stewart A; Leitch M; Ward E
J Natl Cancer Inst; 2008 Apr; 100(7):462-74. PubMed ID: 18364506
[TBL] [Abstract][Full Text] [Related]
3. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
4. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
[TBL] [Abstract][Full Text] [Related]
5. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
6. Patterns of chemotherapy use for women with ovarian cancer: a population-based study.
Cress RD; O'Malley CD; Leiserowitz GS; Campleman SL
J Clin Oncol; 2003 Apr; 21(8):1530-5. PubMed ID: 12697877
[TBL] [Abstract][Full Text] [Related]
7. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
8. The impact of health insurance status on stage at diagnosis of oropharyngeal cancer.
Chen AY; Schrag NM; Halpern MT; Ward EM
Cancer; 2007 Jul; 110(2):395-402. PubMed ID: 17562558
[TBL] [Abstract][Full Text] [Related]
9. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
10. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer: can we make the clinical diagnosis earlier?
Smith LH; Morris CR; Yasmeen S; Parikh-Patel A; Cress RD; Romano PS
Cancer; 2005 Oct; 104(7):1398-407. PubMed ID: 16116591
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with cytoreducibility among women with ovarian carcinoma.
Eltabbakh GH; Mount SL; Beatty B; Simmons-Arnold L; Cooper K; Morgan A
Gynecol Oncol; 2004 Nov; 95(2):377-83. PubMed ID: 15491760
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of cysts in epithelial ovarian cancer.
Kolwijck E; Lybol C; Bulten J; Vollebergh JH; Wevers RA; Massuger LF
Eur J Obstet Gynecol Reprod Biol; 2010 Jul; 151(1):96-100. PubMed ID: 20303211
[TBL] [Abstract][Full Text] [Related]
16. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).
Barnholtz-Sloan JS; Morris R; Malone JM; Munkarah AR
Gynecol Oncol; 2004 May; 93(2):506-12. PubMed ID: 15099970
[TBL] [Abstract][Full Text] [Related]
17. Health insurance and stage at diagnosis of laryngeal cancer: does insurance type predict stage at diagnosis?
Chen AY; Schrag NM; Halpern M; Stewart A; Ward EM
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):784-90. PubMed ID: 17709617
[TBL] [Abstract][Full Text] [Related]
18. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study.
Figueiredo JC; Ennis M; Knight JA; McLaughlin JR; Hood N; O'Malley F; Andrulis IL; Goodwin PJ
Breast Cancer Res Treat; 2007 Sep; 105(1):69-80. PubMed ID: 17115108
[TBL] [Abstract][Full Text] [Related]
19. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States.
Harlan LC; Clegg LX; Trimble EL
J Clin Oncol; 2003 Sep; 21(18):3488-94. PubMed ID: 12972525
[TBL] [Abstract][Full Text] [Related]
20. Insurance status and stage of cancer at diagnosis among women with breast cancer.
Halpern MT; Bian J; Ward EM; Schrag NM; Chen AY
Cancer; 2007 Jul; 110(2):403-11. PubMed ID: 17562557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
